Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
South Korea · Delayed Price · Currency is KRW 5,070.00
-90.00 (-1.74%)
At close: Aug 21, 2026
Kyongbo Pharmaceutical Revenue
Kyongbo Pharmaceutical had revenue of 75.22B KRW in the quarter ending June 30, 2026, with 15.17% growth. This brings the company's revenue in the last twelve months to 279.55B, up 14.83% year-over-year. In the year 2025, Kyongbo Pharmaceutical had annual revenue of 264.10B with 10.71% growth.
Revenue (ttm)
279.55B
Revenue Growth
+14.83%
P/S Ratio
0.43
Revenue / Employee
n/a
Employees
n/a
Market Cap
121.21B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 264.10B | 25.55B | 10.71% |
| Dec 31, 2024 | 238.56B | 22.20B | 10.26% |
| Dec 31, 2023 | 216.36B | 20.09B | 10.24% |
| Dec 31, 2022 | 196.26B | 25.61B | 15.00% |
| Dec 31, 2021 | 170.66B | -44.63B | -20.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jeil Pharma Holdings | 625.97B |
| HANDOK | 560.89B |
| Jeil Pharmaceutical Co.,Ltd | 543.49B |
| Dongwha Pharm.Co.,Ltd | 513.24B |
| Ilyang Pharmaceutical Co.,Ltd | 275.51B |
| HLB Pharmaceutical | 251.95B |
| Samil Pharmaceutical Co.,Ltd | 207.33B |
| Hana Pharm | 139.33B |